Bank of Montreal Can Decreases Position in Omnicell, Inc. $OMCL

Bank of Montreal Can decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 6.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 183,489 shares of the company’s stock after selling 12,840 shares during the period. Bank of Montreal Can owned about 0.39% of Omnicell worth $5,395,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of OMCL. Principal Financial Group Inc. grew its stake in Omnicell by 2.6% during the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company’s stock worth $8,553,000 after purchasing an additional 6,288 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Omnicell by 10.1% in the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock valued at $58,745,000 after buying an additional 154,038 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Omnicell during the first quarter worth about $2,073,000. Wakefield Asset Management LLLP increased its stake in shares of Omnicell by 8.1% during the first quarter. Wakefield Asset Management LLLP now owns 25,517 shares of the company’s stock worth $892,000 after buying an additional 1,906 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in Omnicell in the first quarter worth approximately $10,542,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the transaction, the executive vice president directly owned 110,653 shares of the company’s stock, valued at approximately $3,679,212.25. The trade was a 3.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.52% of the company’s stock.

Omnicell Trading Up 3.2%

Shares of OMCL stock opened at $36.81 on Tuesday. The company has a market capitalization of $1.65 billion, a P/E ratio of 73.62, a price-to-earnings-growth ratio of 6.29 and a beta of 0.95. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $31.65 and its two-hundred day moving average is $30.39. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $50.32.

Wall Street Analyst Weigh In

A number of brokerages have commented on OMCL. Wells Fargo & Company increased their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, July 21st. Benchmark increased their target price on Omnicell from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, October 31st. Wall Street Zen downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Finally, Piper Sandler cut their target price on Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $42.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.